Tamoxifen

Generic Name
Tamoxifen
Brand Names
Soltamox
Drug Type
Small Molecule
Chemical Formula
C26H29NO
CAS Number
10540-29-1
Unique Ingredient Identifier
094ZI81Y45
Background

Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...

Indication

Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.

Associated Conditions
Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
Associated Therapies
Ovulation induction therapy
Clinical Trials
Related News

Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial

First Posted Date
2024-11-04
Last Posted Date
2024-11-04
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
1156
Registration Number
NCT06671912

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

First Posted Date
2024-10-08
Last Posted Date
2024-12-18
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
30
Registration Number
NCT06630325
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

First Posted Date
2024-07-09
Last Posted Date
2024-12-04
Lead Sponsor
Stemline Therapeutics, Inc.
Target Recruit Count
4220
Registration Number
NCT06492616
Locations
🇺🇸

Cancer Centers of Kansas, Wichita, Kansas, United States

🇺🇸

Miami Valley Hospital South, Centerville, Ohio, United States

🇺🇸

Virginia Cancer Institute, Mechanicsville, Virginia, United States

and more 1 locations

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

First Posted Date
2024-06-04
Last Posted Date
2024-10-26
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
540
Registration Number
NCT06440967
Locations
🇨🇦

Site CA15002, Montreal, Quebec, Canada

🇨🇦

Site CA15001, Quebec City, Quebec, Canada

🇨🇦

Site CA15003, Sherbrooke, Quebec, Canada

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

First Posted Date
2024-05-30
Last Posted Date
2024-12-19
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
31
Registration Number
NCT06434064
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Breast Cancer & Antiestrogenic Therapy & Brain

First Posted Date
2024-04-04
Last Posted Date
2024-04-04
Lead Sponsor
International Research Training Group 2804
Target Recruit Count
180
Registration Number
NCT06346457
Locations
🇩🇪

University of Tuebingen; Department of Psychiatry & Psychotherapy Tuebingen, Tuebingen, BW, Germany

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

First Posted Date
2024-04-04
Last Posted Date
2024-11-28
Lead Sponsor
University of Chicago
Target Recruit Count
74
Registration Number
NCT06348134
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer

First Posted Date
2024-01-25
Last Posted Date
2024-11-19
Lead Sponsor
Region Örebro County
Target Recruit Count
3832
Registration Number
NCT06223698
Locations
🇸🇪

Karolinska University Hospital, Stockholm, Sweden

🇸🇪

University Hospital of Umeå, Umeå, Sweden

🇸🇪

Akademiska University Hospital Uppsala, Uppsala, Sweden

and more 7 locations

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

First Posted Date
2024-01-08
Last Posted Date
2024-01-08
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
66
Registration Number
NCT06195306
Locations
🇺🇸

University of Kansas Cancer Center, Kansas City, Kansas, United States

🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

First Posted Date
2023-12-28
Last Posted Date
2024-12-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
200
Registration Number
NCT06184750
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

and more 8 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy